Sai Life Sciences IPO

About the company

Sai Life Sciences Limited is a contract research, development, and manufacturing organisation (CRDMO) founded in 1999. The company provides end-to-end services across the drug discovery, development, and manufacturing value chain to global pharmaceutical and biotechnology companies. The company’s CRO and CDMO services span early drug discovery, clinical trial support, and commercial drug manufacturing, with a portfolio of 170+ innovator pharmaceutical products. In FY24, revenue from CRO business made up 33.85% of total revenue, while the rest was contributed by the company’s CDMO business. Meanwhile, revenue from its top ten customers made up 46.2% of overall revenue.

Financial performance (₹ Cr)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   11 Dec 2024

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   13 Dec 2024

   Last day to place your bid

3. Basis of Allotment

   Completed
   16 Dec 2024

   Share allotment finalised

4. Refund Initiation

   Completed
   17 Dec 2024

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   17 Dec 2024

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   18 Dec 2024

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.